Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....

TECHNOLOGY: Tissue markers Counts of F. nucleatum bacteria in tumor mucosae could help predict responses to oxaliplatin and Xeloda combination therapy in colorectal cancer patients. In 31 patients, high counts of F. nucleatum in tumor...

FDA accepted an NDA from Eagle for pemetrexed RTD as monotherapy to treat locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and in combination with cisplatin to treat mesothelioma. The PDUFA date is...

Eagle said it submitted an NDA to FDA for pemetrexed RTD to treat locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and mesothelioma in combination with cisplatin. The product is a ready-to-dilute, IV...

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting ARPC3 in combination with angiogenesis inhibitors could help treat metastatic colorectal cancer. In patients treated with Avastin bevacizumab, high levels of ARPC3 in...

The U.K.’s NICE issued final guidance recommending the use of Alimta pemetrexed from Eli Lilly as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose disease has...

The U.K.’s NICE issued final draft guidance recommending Alimta pemetrexed from Eli Lilly as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose disease has not progressed...

In a final draft guidance, the U.K.'s NICE recommended Alimta pemetrexed from Eli Lilly and Co. (NYSE:LLY) as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose...

Cancer INDICATION: Liver cancer In vitro and mouse studies identified an oral phosphoramidate-based prodrug of the TYMS inhibitor floxuridine that could help treat hepatocellular carcinoma (HCC). Chemical synthesis of benzylamine phosphoramidate analogs of floxuridine followed...

Disease models TECHNOLOGY: Cell models Genetically engineered human iPS cell-derived models of gliomagenesis could be used to screen therapies for brain cancer. The cell models were generated from two sets of human iPS cells by...